Navigation Links
University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education
Date:10/2/2007

Serious subject for the funnies becomes basis for Lisa's Legacy Fund

CLEVELAND, Oct. 2 /PRNewswire/ -- For the first time in a comic strip, Funky Winkerbean creator Tom Batiuk has depicted the death of a young wife and mother from the recurrence of breast cancer. Lisa Moore, a major character who is battling breast cancer for a second time, succumbs to the disease on Oct. 4, 2007, leaving behind her husband, Les, and their five-year-old daughter, Summer.

As a result of Batiuk's commitment to helping people facing their own real life battles with cancer, University Hospitals Ireland Cancer Center in Cleveland has unveiled a fund called Lisa's Legacy Fund for Cancer Research and Education, named in honor of Batiuk's character and her subsequent story which has resonated with thousands of readers.

The University Hospitals Ireland Cancer Center is one of only 40 comprehensive cancer centers in the United States, as designated by the National Institutes of Health. Currently in its 19th year of operation, it is a leading center for patient care, cancer research, and community education about cancer care. One hundred percent of the donations to Lisa's Legacy Fund will go to cancer research and education at Ireland Cancer Center. Ongoing research includes work on the development of a vaccine for breast cancer, a blood test for colon cancer, breakthrough chemotherapy treatments for all types of cancer featuring new drugs developed by the Center's clinician- scientists, and new approaches to radiation treatments. Ireland Cancer Center is one of only eight cancer centers in the country to have access to a pipeline of new drugs through the National Cancer Institute for early phase clinical trials.

Batiuk has granted UH Ireland Cancer Center permission to use Lisa's name and likeness to raise funds for cancer research and education. Additionally, Batiuk and King Features Syndicate, a Unit of Hearst Corporation, will donate all royalties from his b
'/>"/>

SOURCE University Hospitals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Researchers at Cornell University as been reported using research fund by false claims
2. A new study by John Hopkins University proposes formula for good health
3. James Cook University urges more medical seats
4. Pill splitting program of University of Michigan can save money
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Yale University guidelines for Physicians and Pharmaceutical industry
7. $ 1.7 Million NYSTAR Award for Binghamton University to Flex Electronics Research Muscle.
8. Florida State University declares a breathtaking study which might solve the Hepatitis C Virus maze and find a cure!
9. Hwang Woo Suk Suspended By Seoul National University
10. Vladeck to head the University of Medicine and Dentistry of New Jersey
11. Rice University wins Prestigious Grants from HHMI
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 1Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 1Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 2Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 4Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 5Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 1Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 2